Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial ( LEOPOLD II)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial ( LEOPOLD II)

Published:2015-01-30 Issue:3 Volume:13 Page:360-369
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Kavakli K.¹,Yang R.²,Rusen L.³,Beckmann H.⁴,Tseneklidou‐Stoeter D.⁵,Maas Enriquez M.⁴,Yang Renchi,Zhao Yongqiang,Sun Jing,Wang Xuefeng,Wu Depei,Hlusi Antonin,Fukutake Katsuyuki,Hanabusa Hideji,Fujii Teruhisa,Ramírez Oscar Pérez,Alvarado Blanca Salazar,Serban Margit,Rusen Luminita,Uscatescu Valentina,Truica Cristina,Kostic Gordana,Konstantinidis Nada,Igrutinovic Zoran,Perina Farida,Andreeva Tatiana,Kavakli Kaan,Antmen Bulent,Sasmaz Ilgen,Kupesiz Alphan,Yesilipek Mehmet Akif,Peng Ching‐Tien,French James,Escobar Miguel,Mahlangu Johnny,Pool Roger

Affiliation:

1. Ege University Children's Hospital Izmir Turkey

2. Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin China

3. S.C. SANADOR SRL Bucharest Romania

4. Bayer Pharma AG WuppertalGermany

5. Bayer Pharma AG Berlin Germany

Funder

BAYER HEALTHCARE AG

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.12828

Reference21 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

3. Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy

4. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries

5. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology;Journal of Thrombosis and Haemostasis;2024-09

2. On-demand versus prophylactic therapy with factor VIII concentrate in patients with hemophilia A: Differences in efficacy and quality of life: A multicenter study;Medical Journal of Babylon;2023-12

3. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India;Hematology;2023-11-07

4. Neurological Complications Associated with Hereditary Bleeding Disorders;Current Neurology and Neuroscience Reports;2023-10-21

5. Unmet needs for severe hemophilia A cases without inhibitors in Argentina: a cross-sectional study.;Revista Hematología;2023-09-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3